Retatrutide Takes Weight Off. Viking Bets a Monthly Shot Keeps It

The obesity drug business has two problems, and this autumn each got its own headline. The first is how much weight a drug can take off. Eli Lilly answered with retatrutide, which in a phase 3 trial of people with obesity and type 2 diabetes removed about a fifth of body weight. The second is what happens afterward, when people try to keep the weight off without a weekly injection for life. Viking Therapeutics answered with a small study in which a once monthly shot kept up to 90% of the lost weight. Both numbers are real. Both are also the most flattering version of the data, and the less flattering versions are worth knowing.

TRIUMPH-2: the trial and the two numbers

Retatrutide hits three hormone receptors at once: GIP, GLP-1 and glucagon. TRIUMPH-2, published in The Lancet on September 29 and presented at the European Association for the Study of Diabetes meeting in Milan, randomized 1,152 adults at 92 sites in eight countries to one of three doses or a placebo, injected weekly for 80 weeks. Participants had type 2 diabetes and a BMI of 27 or more; their average age was 55, average BMI 38.2, and 92% were already taking oral diabetes drugs.

Lilly's press release leads with 20.8% weight loss on the highest dose. That figure uses what statisticians call the efficacy estimand: the result had every participant stayed on the drug for the full 80 weeks. The paper's primary analysis uses the treatment regimen estimand, which counts people as they actually behaved, including those who stopped. On that measure, the highest dose produced 18.8% weight loss and placebo 5.1%, a difference of 13.8 percentage points. The middle dose came in at 16.8% and the lowest at 11.9%. All differences against placebo were highly significant.

Neither number is wrong. They answer different questions. The first is what the molecule can do. The second is closer to what a population of real patients gets. When you compare drugs across press releases, check which one you are reading; our guide to reading a health study in five minutes covers exactly this kind of trap.

The 20.8% describes a trial in which nobody quits. The 18.8% describes the trial that actually happened.

What came with the weight loss

Blood sugar improved sharply: average A1C fell by 1.4 to 1.6 points from a starting 7.7%, and up to 40% of participants reached an A1C below 5.7%, the normal range, according to Lilly. On the highest dose, 59.5% of participants no longer met the BMI definition of obesity. Lilly also reports lower triglycerides, blood pressure and inflammation markers.

The costs are familiar from the class, with a few additions. Diarrhea hit about a third of people on the two higher doses against 13% on placebo, and nausea up to 28% against 8%. Low blood pressure and dysesthesia, an abnormal skin sensation, were more frequent with retatrutide. Permanent discontinuation for adverse events or death reached 12% on the middle dose and 8% on the highest, against 5% on placebo. Seven people died during the trial, six of them on retatrutide, and investigators judged all deaths unrelated to the drug. Lilly says it will file for FDA approval in the first quarter of 2027.

Viking's monthly shot: read the table, not the headline

Viking's drug, VK2735, targets two receptors, GLP-1 and GIP, like tirzepatide. Its maintenance study, announced September 22 in a company press release, enrolled about 180 adults with obesity and without diabetes. Everyone first took weekly injections, or placebo, for 21 weeks and lost roughly 16% to 19% of body weight on the drug. Then participants were moved to less frequent schedules for 12 more weeks: every other week, once a month, or placebo.

The 90% figure is the best of five monthly cohorts, a group of 11 people. Across all 65 people on monthly dosing, the average was 85% of their lost weight kept at week 33. The every other week cohorts did better, 90% combined and up to 97% in a group of 12. The comparison that matters most sits at the bottom of the table: people switched to placebo still kept 61% of their loss after three months. That is the real baseline. Monthly dosing added roughly 24 percentage points over stopping entirely, and it did so over 12 weeks, which is short for anything called maintenance.

The study's stated objectives were safety, tolerability and drug levels; weight maintenance was an exploratory endpoint. Viking reports that stomach side effects during the maintenance phase were similar to placebo, which is plausible with smaller, rarer doses. The data have not been peer reviewed.

What comes next

For retatrutide, the open questions are the ones a phase 3 paper cannot fully answer: whether the extra weight loss over existing drugs justifies the higher discontinuation rate, how the drug performs in people without diabetes in head to head comparisons, and what the agency makes of the safety file next year. For Viking, the next steps are a second part of the study testing oral maintenance and much longer follow up. The obesity field has moved quickly, as our look at the orforglipron and oral semaglutide duel shows, and the maintenance question is now where the competition is moving.

I find the Viking result more interesting than the retatrutide headline, and more fragile. Bigger weight loss numbers are now a race with diminishing returns: a few extra points matter less to most patients than whether they can stay on a drug, afford it, and tolerate it for years. A shot twelve times a year instead of fifty two would change that calculation for a lot of people. But the most important number in Viking's release is the 61% kept on placebo three months after stopping, because it tells you how much weight a short study cannot yet show coming back. My guess is that maintenance dosing becomes standard practice within a few years. The evidence that it works at one year, though, does not exist yet, and anyone weighing these options should have that conversation with their own doctor rather than with a press release.